Edition:
United States

Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

1.74EUR
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
€1.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,635
52-wk High
€2.90
52-wk Low
€1.56

Chart for

About

Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's... (more)

Overall

Beta: 1.01
Market Cap(Mil.): €31.10
Shares Outstanding(Mil.): 17.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 57.15 15.71
EPS (TTM): -- -- --
ROI: -- 13.34 31.93
ROE: -- 19.96 16.16

BRIEF-Stentys announces the pre-commercialization of SERPENTIS

* STENTYS ANNOUNCES THE PRE-COMMERCIALIZATION OF SERPENTIS, ITS NEW LATEST-GENERATION OF ACTIVE STENT

Nov 08 2017

BRIEF-Stentys Q3 revenues of 1.6 million, down 4.7%

* ‍DURING Q3 OF 2017, STENTYS RECORDED REVENUES OF EUR 1.6 MILLION, DOWN 4.7% YOY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 12 2017

BRIEF-Stentys H1 recurring operating loss narrows to 2.7 million euros

* H1 NET LOSS EUR 3.0 MILLION VERSUS LOSS OF EUR 4.1 MILLION YEAR AGO

Oct 02 2017

BRIEF-Stentys completes enrollment Xposition S study

* SAID ON THURSDAY COMPLETS ENROLLMENT IN STUDY ASSESSING THE SAFETY AND EFFICACY OF XPOSITION S IN LEFT MAIN ARTERY LESIONS

Jul 28 2017

BRIEF-Stentys Q2 revenue eur 1.7 million

* Q2 REVENUE EUR 1.7 MILLION VERSUS EUR 2.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 12 2017

Earnings vs. Estimates